II
CRNX icon

Inspire Investing’s Crinetics Pharmaceuticals CRNX Stock Holding History

Inspire Investing’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23 Hold
1
– – ﹤0.01% 1095
2025
Q4 		$29 Buy
+1
New +$45 ﹤0.01% 1091

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Inspire Investing's CRNX Position: Q1 2026 in Review

Inspire Investing held its Crinetics Pharmaceuticals (CRNX) position steady in Q1 2026 at 1 share worth $23. The position accounts for ﹤0.01% of the portfolio, ranked #1095.

Inspire Investing first reported a position in CRNX in Q4 2025 and has held it in 2 quarters since. The position peaked at $29 in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Inspire Investing held 1 share of Crinetics Pharmaceuticals worth $23 as of Q1 2026.
  • Inspire Investing left its Crinetics Pharmaceuticals share count unchanged in Q1 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Inspire Investing's portfolio in Q1 2026, its #1095 holding.
  • Inspire Investing first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Inspire Investing's Crinetics Pharmaceuticals position peaked at $29 in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Inspire Investing's 13F filing for Q1 2026, filed 23 Apr 2026.